Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoLife

This article was originally published in The Gray Sheet

Executive Summary

Going public via offering of 1.5 mil. shares at an estimated price of $9.50 per share; CryoLife is offering 1 mil. of the shares, while existing shareholders are selling 500,000 shares. Underwriting the deal is The Robinson-Humphrey Company and Morgan Keegan & Co. CryoLife, which cryopreserves human heart valves, saphenous veins, and orthopedic tissues, will use $2.1 mil. of the expected $8.2 mil. in net proceeds to repay debt. The remaining proceeds will be used for working capital, including $700,000 to cover expenses associated with obtaining FDA approval of the firm's human heart valves and $2 mil. for ongoing research and development. Among products/technologies under development are viral inactivation processes for bone, soft tissue and blood products that decontaminate microorganisms such as hepatitis B and human immunodeficiency viruses. Also under development is: FibRx, a surgical bio-adhesive based on a derivative of fibrinogen, "which, if successful, may control bleeding and assist in positioning tissue at wound sites during and after surgery"; SynerGraft, a process for transplanting human cells onto the structure of a non-viable animal tissue that could alleviate "donor supply constraints associated with human tissue"; a technique for red blood cell cryopreservation; and "improved fluids for tissue transport and cardioplegia".

You may also be interested in...



Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

UsernamePublicRestriction

Register

MT000190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel